RecruitingPhase 3

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

United States3,040 participantsStarted 2025-09-22

Plain-language summary

A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis

Age range40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Deemed by the Investigator to be a candidate for phototherapy or systemic treatment for psoriasis, including ustekinumab;
✓. Have at least 1 of the following cardiovascular risk factors:

Composite cardiovascular adjudicated 3-point major adverse cardiovascular event (MACE) plus coronary revascularization

Timeframe: Up to 5 years

NCT IDNCT07116967

SponsorBristol-Myers Squibb

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2031-01-16

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com